Alto Neuroscience, Inc. (ANRO) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Alto Neuroscience, Inc. stock $21.13, price $27.12, that is 22.1% below the price, quality 32 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Alto Neuroscience, Inc.
ANRO · USExpensive (fair value 22% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
33‑month range $1.80 – $36.64 · fair‑value band $15.85 – $26.42 · the $27.12 price screens above the $21.13 fair value. As of Nov 14, 2026.
Every Wednesday you see whether Alto Neuroscience is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Show moreShow less
The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease.
The company was incorporated in 2019 and is headquartered in Mountain View, California.
Stock analysis
Alto Neuroscience, Inc. (ANRO) currently trades at $27.12, while our estimate is $21.13, 22% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $15.85 (bear) to $26.42 (bull), the price of $27.12 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Alto Neuroscience, Inc. reported revenue of $0 in FY2025 versus $210K in FY2021. Reported net income was −$63.2M in FY2025.
Key figures
Market cap $1.2B Small · EPS (TTM) $−2.32 · Return on equity −46.7% · Return on assets (EBIT) −43.5% (5-year average) · Free cash flow −$51.8M · Net cash $172M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 112% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −22%, ANRO screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director sold shares worth $3.6M and none bought.
- SaleNicholas Conrad SmithPRESIDENT AND CFO134,886 shares at $26.45$3.6MSep 30, 202610b5-1 plan
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Earlier news
- Here's Why You Should Add ANRO Stock to Your Portfolio Now
- Alto Neuroscience promotes Nick Smith to president & CFO
- Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACAD
- Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX
Compare Alto Neuroscience, Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs ANRO |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs ANRO |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs ANRO |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs ANRO |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs ANRO |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs ANRO |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs ANRO |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs ANRO |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs ANRO |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs ANRO |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Alto Neuroscience, Inc. (ANRO) overvalued or undervalued?
What is the fair value of ANRO?
What is the quality score of ANRO?
What is the price target for Alto Neuroscience, Inc. (ANRO)?
What is the Alto Neuroscience, Inc. stock forecast for 2026?
What is the intrinsic value of Alto Neuroscience, Inc. (ANRO)?
Is Alto Neuroscience, Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ANRO?
How much is Alto Neuroscience, Inc. worth?
What do the bullish and bearish scenarios say about ANRO?
How solid is the balance sheet of Alto Neuroscience, Inc. (ANRO)?
How far is ANRO from its 52-week high?
Which stocks are comparable to Alto Neuroscience, Inc.?
Is Alto Neuroscience, Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Alto Neuroscience, Inc. (ANRO)?
What should I pay attention to with Alto Neuroscience, Inc. right now?
Key figures of Alto Neuroscience, Inc.
How large is the market capitalisation of Alto Neuroscience, Inc. (ANRO)?
What are the earnings per share of Alto Neuroscience, Inc. (ANRO)?
What is the return on equity of Alto Neuroscience, Inc. (ANRO)?
What is the EBIT return on assets of Alto Neuroscience, Inc. (ANRO)?
How much free cash flow does Alto Neuroscience, Inc. (ANRO) generate?
How much net cash does Alto Neuroscience, Inc. (ANRO) hold?
Watch Alto Neuroscience, Inc. in the live analysis
One click puts Alto Neuroscience, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.